Somewhat Positive Press Coverage Somewhat Unlikely to Impact NantHealth (NH) Stock Price

Press coverage about NantHealth (NASDAQ:NH) has been trending somewhat positive on Monday, Accern Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NantHealth earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news articles about the company an impact score of 47.2896596899392 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:

NantHealth (NASDAQ:NH) traded down $0.23 during trading on Monday, hitting $2.99. 394,246 shares of the stock were exchanged, compared to its average volume of 204,736. NantHealth has a 1 year low of $2.60 and a 1 year high of $11.95. The company has a quick ratio of 2.36, a current ratio of 2.38 and a debt-to-equity ratio of 0.93.

NantHealth (NASDAQ:NH) last released its earnings results on Thursday, November 9th. The company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.01. NantHealth had a negative net margin of 105.77% and a negative return on equity of 36.30%. The firm had revenue of $21.76 million during the quarter, compared to the consensus estimate of $29.42 million. During the same period in the prior year, the firm earned ($0.18) EPS. The company’s revenue was up 5.3% compared to the same quarter last year. equities analysts expect that NantHealth will post -1.35 EPS for the current fiscal year.

NH has been the subject of a number of recent analyst reports. Canaccord Genuity reaffirmed a “buy” rating and issued a $6.00 price objective (down from $8.00) on shares of NantHealth in a research report on Monday, August 21st. Jefferies Group reduced their price objective on shares of NantHealth from $5.50 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, August 23rd. BidaskClub raised shares of NantHealth from a “strong sell” rating to a “sell” rating in a research report on Friday, September 8th. Finally, Zacks Investment Research raised shares of NantHealth from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a research report on Thursday, October 12th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $8.00.

In other news, COO Ronald Allen Louks sold 26,820 shares of the stock in a transaction that occurred on Friday, October 6th. The shares were sold at an average price of $4.28, for a total transaction of $114,789.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 58.00% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/04/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-nanthealth-nh-stock-price.html.

About NantHealth

NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.

Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply